SLC10A3 Is a Prognostic Biomarker and Involved in Immune Infiltration and Programmed Cell Death in Lower Grade Glioma

Ma, Weibo; Mei, Pengying

doi:10.1016/j.wneu.2023.07.134

Cited by 2 publications

(3 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In terms of LGG, higher DXS253E expression levels contribute to programmed cell death and immune infiltration, resulting in poor prognosis of the patients with LGG [ 40 ]. Consistently, Ma et al also found that the upregulation of DXS253E is associated with poor OS in LGG and glioblastoma [ 41 ]. Moreover, they suggested that SLC10A3 is a possible therapeutic target for LGG [ 41 ].…”

Section: Discussionmentioning

confidence: 60%

“…Consistently, Ma et al also found that the upregulation of DXS253E is associated with poor OS in LGG and glioblastoma [ 41 ]. Moreover, they suggested that SLC10A3 is a possible therapeutic target for LGG [ 41 ]. Furthermore, Wang et al’s study that analyzed public databases indicates that a high DXS253E expression predicts poor prognosis in CRC patients, and they propose that it could be used as an immunotherapy target in CRC given its significant influence on the immune microenvironment [ 23 ].…”

Section: Discussionmentioning

confidence: 60%

“…We also investigated the DEGs between DXS253E low- and DXS253E high-expression groups in CRC to elucidate the potential biological functions and regulatory pathways of DXS253E. A previous study using GO/KEGG enrichment analysis demonstrated that DXS253E-correlated genes were related to substance transport in LGG [ 41 ]. However, we identified that DXS253E affected the transcriptome and oxidative phosphorylation metabolic pathway in CRC by conducting enrichment analyses of the GO and KEGG databases and GSEA.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Integrated profiling identifies DXS253E as a potential prognostic marker in colorectal cancer

Xing,

Hao,

Chen

et al. 2024

Cancer Cell Int

View full text Add to dashboard Cite

Background Increasing evidence suggests that DXS253E is critical for cancer development and progression, but the function and potential mechanism of DXS253E in colorectal cancer (CRC) remain largely unknown. In this study, we evaluated the clinical significance and explored the underlying mechanism of DXS253E in CRC. Methods DXS253E expression in cancer tissues was investigated using the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. The Kaplan-Meier plot was used to assess the prognosis of DXS253E. The cBioPortal, MethSurv, and Tumor Immune Estimation Resource (TIMER) databases were employed to analyze the mutation profile, methylation, and immune infiltration associated with DXS253E. The biological functions of DXS253E in CRC cells were determined by CCK-8 assay, plate cloning assay, Transwell assay, flow cytometry, lactate assay, western blot, and qRT-PCR. Results DXS253E was upregulated in CRC tissues and high DXS253E expression levels were correlated with poor survival in CRC patients. Our bioinformatics analyses showed that high DXS253E gene methylation levels were associated with the favorable prognosis of CRC patients. Furthermore, DXS253E levels were linked to the expression levels of several immunomodulatory genes and an abundance of immune cells. Mechanistically, the overexpression of DXS253E enhanced proliferation, migration, invasion, and the aerobic glycolysis of CRC cells through the AKT/mTOR pathway. Conclusions We demonstrated that DXS253E functions as a potential role in CRC progression and may serve as an indicator of outcomes and a therapeutic target for regulating the AKT/mTOR pathway in CRC.

show abstract

Section: Discussionmentioning

confidence: 60%

Section: Discussionmentioning

confidence: 60%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Integrated profiling identifies DXS253E as a potential prognostic marker in colorectal cancer

Xing,

Hao,

Chen

et al. 2024

Cancer Cell Int

View full text Add to dashboard Cite

show abstract

Elucidating the impact of parthanatos-related microRNAs on the tumoral immune microenvironment and clinical outcome in low-grade gliomas

Zhu,

Wu,

Zheng

et al. 2024

Discov Onc

View full text Add to dashboard Cite

Parthanatos, a cell death mechanism triggered by PARP-1 activation, is implicated in oncogenic processes, yet their role in low-grade gliomas (LGG) remains poorly understood. This research investigates Parthanatos-related miRNAs' prognostic and immunomodulatory potential, alongside their influence on therapeutic outcomes in LGGs. Comprehensive miRNA and mRNA profiles of LGG patients were extracted from TCGA and CGGA databases, integrating clinical parameters to identify Parthanatos-associated miRNAs. IHC data validated the expression levels of Parthanatos-related genes in glioma versus normal brain tissues. Protein–protein interaction networks and Spearman correlation analysis facilitated the identification of key miRNAs. Parthanatos-related miRNA indices (PMI) were screened using Lasso and assessed for their accuracy in predicting prognosis, comparing their associated potential molecular functions and heterogeneity of the immune microenvironment. Drug sensitivity was assessed between different groups and optimal therapeutic agents were predicted. Validate the expression levels of key miRNAs by qPCR. Ninety-one miRNAs significantly associated with Parthanatos were screened, through which a PMI prognosis model of nine miRNAs was constructed. The PMI score was able to independently predict the prognosis of patients with LGG, and the nomogram constructed based on the PMI provided a practical tool for clinical prediction of patient prognosis. The proportion of immune response was lower in patients in the high-risk group, and there were significant differences in drug sensitivity between different risk classes, while drugs such as Fasudil were identified as the most promising therapeutic agents for patients in the high-risk group. Our findings highlight the critical role of Parthanatos-associated miRNAs in the progression and treatment of LGG, offering novel insights into their prognostic value and therapeutic potential.

show abstract

SLC10A3 Is a Prognostic Biomarker and Involved in Immune Infiltration and Programmed Cell Death in Lower Grade Glioma

Cited by 2 publications

References 82 publications

Integrated profiling identifies DXS253E as a potential prognostic marker in colorectal cancer

Integrated profiling identifies DXS253E as a potential prognostic marker in colorectal cancer

Elucidating the impact of parthanatos-related microRNAs on the tumoral immune microenvironment and clinical outcome in low-grade gliomas

Contact Info

Product

Resources

About